Alaska Clinical Trials Report — April 2026

For Alaskans considering participation in medical research, April 2026 brings a focused set of opportunities, particularly for patients with specific health conditions. A critical window is closing rapidly, with 4 clinical trials across Alaska slated to conclude enrollment within the next 90 days. These studies are specifically for individuals managing complex health challenges, and notably, 0 of these impending closures are accepting healthy volunteers. This means that for those eligible, time is of the essence to explore these research avenues before they are no longer available.

The trials nearing their enrollment deadlines address a range of serious conditions, primarily in oncology and smoking cessation. Patients with these diagnoses who have been considering trial participation should act quickly to determine their eligibility. Conditions with trials closing soon include:

• Advanced NSCLC (non-small cell lung cancer)
• Anatomic Stage II Breast Cancer AJCC V8
• Anatomic Stage III Breast Cancer AJCC V8
• HER2-Negative Breast Carcinoma
• Hormone Receptor-Positive Breast Carcinoma
• Metastatic Lung Cancer
• Recurrent Lung Non-Small Cell Carcinoma
• Smoking Cessation
• Stage IV Lung Cancer AJCC V8

A Significant New Opportunity in Pancreatic Cancer Research

This month, Alaska welcomes a notable new clinical trial, a significant Phase 3 study sponsored by Incyte Corporation. This trial represents a major opportunity for patients dealing with a challenging form of cancer, bringing cutting-edge research to the state.

• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This Phase 3 drug trial aims to enroll 588 participants globally, with sites in Alaska contributing to this important effort. The study's purpose is to evaluate the efficacy and safety of standard chemotherapy when combined with or without the investigational drug INCB161734 in individuals with metastatic pancreatic ductal adenocarcinoma (PDAC) that carries a specific KRAS G12D mutation. This type of research is crucial for advancing treatment options for solid tumors.

This new trial is the sole addition to Alaska's research landscape this month, matching the single new trial that opened in December 2025. It is a significant industry-sponsored drug trial, focusing on a critical area of unmet medical need.

Geographic Reach and Healthy Volunteer Options

The new trial this month is located in Anchorage, reinforcing the city's role as a primary hub for clinical research within Alaska. While only 1 new trial opened this month, the state currently has 119 clinical trials actively recruiting across 7 cities and 43 research sites. This broad distribution ensures that opportunities are available beyond the largest metropolitan areas, enhancing accessibility for residents across the state.

For individuals without a specific medical condition, opportunities to contribute to medical science remain available. While the new trial this month does not accept healthy volunteers, there are still 12 clinical trials statewide that are actively recruiting healthy participants. These trials play a vital role in establishing baseline data and evaluating the safety of new interventions in individuals without underlying health issues. Those interested in participating as a healthy volunteer should explore these existing options.

Regarding participant demographics, the new Incyte Corporation trial is designed to include older adults, ensuring that this important population group has the chance to participate in advanced cancer research. No new trials this month are specifically for children, or exclusively for female or male participants.

As spring progresses, the focus for Alaskans interested in clinical trials will be on the ongoing enrollment for existing studies, particularly the significant Phase 3 pancreatic cancer trial, and the limited window remaining for those trials nearing their closure dates.